MeTC7
Based on 5 publication(s) in Google Scholar
MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.50%
- CAS No.: 1817841-22-7
- Formule: C32H48BrN3O4
- Masse moléculaire:618.65
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) MeTC7
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
-
Cell Imaging/Staining
-
WB
Activité biologique
IC50: 2.9 μM (VDR)[1].
MeTC7 (compound 5) shows potent VDR inhibition activity with an IC50 value of 2.9 μM[1].
MeTC7 disrupts the VDR-Ligand-binding domain in Silico[1].
MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line[1].
MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:2008 cells
-
Concentration:250 nM
-
Incubation Time:18, 12 h
-
Result:Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells.
-
Cell Line:SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines
-
Concentration:0, 0.25, 0.5, 0.75, 1.0, 1.25 μM
-
Incubation Time:24 h
-
Result:Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice[1]
-
Dosage:10 mg/kg
-
Administration:IP
-
Result:Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells.
Inhibited the growth of neuroblastoma cells and Xenografts.
Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.
Chemical Information
-
CAS No. 1817841-22-7
-
Appearance Solid
-
Masse moléculaire 618.65
-
Formule C32H48BrN3O4
-
Color White to off-white
-
SMILES
O=C1N2C34[C@@](CC[C@]5([C@@]4([H])CC[C@]5([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6(C(C=C3)(C[C@H](CC6)OC(CBr)=O)N2C(N1C)=O)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas. [Abstract]2025 Oct;37(40):e2507657. PMID: 40504743
MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Oct;37(40):e2507657. [Abstract]
Schematic representation of VDR blockade using MeTC7. Mice were administered 50 mg/kg of MeTC7 intraperitoneally, and 12 h later, mRNA LNPs were administered intravenously.
MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Oct;37(40):e2507657. [Abstract]
To investigate the role of VDR, mice were pre-administering with VDR antagonist MeTC7 or PBS (control) 12 h before LNP administration. Representative IVIS images at 24 h post-injection of LNPs (0.5 mg/kg) in C57BL/6 mice (n = 4 biologically independent mice). Organs are arranged left to right as: heart, lung, spleen, pancreas, liver, kidneys and intestines.
-
Phytother Res
Betulinic Acid Enema Alleviates Colitis by Targeting Vitamin D Receptor to Protect the Intestinal Mucosal Barrier and Modulate Mucosa-Associated Microbiota. [Abstract]2026 Jun 18. PMID: 42316556 -
Eur J Pharmacol
Calcitriol deficiency reduces myocardial ATP production with disturbed mitochondrial dynamics and increased uncoupling protein 2 expression. [Abstract]2025 Sep 5:1002:177858. PMID: 40553779 -
Int J Mol Sci
DKS26 Alleviates Ischemia-Reperfusion Injury-Induced Acute Kidney Injury by Stabilizing Vitamin D Receptors to Inhibit the Inflammatory Pathway of NF-κB P65. [Abstract]2025 Mar 25;26(7):2985. PMID: 40243616
MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]
Western blot detection of p-P65Ser311, P65, TNFα, MCP-1, KIM1, and NGAL expression in cells after administration of MeTC7 and/or DKS26-treated mRETCs; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.
MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]
Effects of MeTC7 and DKS26 on the nuclear translocation of p-P65Ser311 (red) observed by laser confocal microscopy.
MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]
Western blot analysis of p-IKKβ, IKKβ, p-IKBα, and IKBα expression in cells treated with DKS26 and/or MeTC7; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.
-
Biochem Biophys Rep
Exercise-induced vitamin D receptor and androgen receptor mediate inhibition of IL-6 and STAT3 in muscle. [Abstract]2023 Dec 21:37:101621. PMID: 38205185
Solvant et solubilité
DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6164 mL | 8.0821 mL | 16.1642 mL | 40.4106 mL |
| 5 mM | 0.3233 mL | 1.6164 mL | 3.2328 mL | 8.0821 mL | |
| 10 mM | 0.1616 mL | 0.8082 mL | 1.6164 mL | 4.0411 mL | |
| 15 mM | 0.1078 mL | 0.5388 mL | 1.0776 mL | 2.6940 mL | |
| 20 mM | 0.0808 mL | 0.4041 mL | 0.8082 mL | 2.0205 mL | |
| 25 mM | 0.0647 mL | 0.3233 mL | 0.6466 mL | 1.6164 mL |
MeTC7 Related Classifications
HY-147337 Related Classifications
Powered by Bioz